Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548472 | 0.97 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4ACHECXCR2 | |
| SCHEMBL1958265 | 0.95 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4ACHECXCR2 | |
| SCHEMBL6498188 | 0.84 | F2 (0.35) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL1957632 | 0.84 | ADORA1 (0.38) | SLC6A3 | |
| SCHEMBL502170 | 0.83 | CXCR2 (0.31) | CXCR2 | |
| SCHEMBL524286 | 0.81 | CXCR2 (0.30) | CXCR2 | |
| SCHEMBL1677588 | 0.81 | CXCR2 (0.30) | CXCR2 | |
| SCHEMBL17972852 | 0.81 | HSD11B1 (0.35) | CXCR2 | |
| SCHEMBL1743472 | 0.81 | ADORA1 (0.38) | — | |
| SCHEMBL6503256 | 0.80 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732837-A2 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4263545-B1 | PRMT5 INHIBITORS | AMGEN INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025119351-A1 | GPR139 AGONIST | 深圳湾实验室 | 2025-06-12 | — | — | WO | disclosed |
| US-20250163022-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4536642-A1 | HETEROCYCLIC COMPOUNDS AS PI3KA INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024255697-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| US-20240368169-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4452963-A1 | PARP1 INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-116217386-B | Carboxylic acid compound and preparation method and application thereof | 五邑大学 | 2024-09-24 | — | — | CN | disclosed |
| US-20060199858-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-09-07 | — | — | US | disclosed |
| EP-1618102-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004094401-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004043349-A2 | ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040082563-A1 | Phenyl derivatives 3 | MERCK PATENT GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1368341-A1 | PHENYL DERIVATIVES 3 | MERCK PATENT GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002074765-A1 | PHENYL DERIVATIVES 3 | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |
| EP-1214303-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016121-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368169-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | PARP1, PARP2, PARP11 | SLC6A3 4793/4885SLC6A2 4759/4885SLC6A4 4627/4885 |
| US-20060199858-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | GPER1, ESR2, ESR1 | SLC6A3 1166/4885SLC6A2 1694/4885SLC6A4 1300/4885 |
| US-20040082563-A1 | Phenyl derivatives 3 | F2, F11, F12 | SLC6A3 3942/4885SLC6A2 4483/4885SLC6A4 4440/4885 |
| US-20250163022-A1 | PARP1 INHIBITORS | PARP1, PARP11, PARP12 | SLC6A3 4470/4885SLC6A2 4708/4885SLC6A4 4718/4885 |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | SLC6A3 2879/4885SLC6A2 2550/4885SLC6A4 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.